Chataway
Genetics
apitope
Belgium
Biography
Chataway is the clinical lead of the MS group at the NHNN (about 3000 patients) and was a member of the 2014 MS NICE panel. He has a particular interest in clinical trial design and was the Chief Investigator (CI) of the recently reported MS-STAT1 trial in secondary progressive MS, using high dose simvastatin; and is the CI of the currently recruiting MRC/EME MS-SMART trial, again in secondary progressive MS
Research Interest
Genetics
